

1 **Distinct COVID-19 vaccine combinations result in** 2 **divergent immune responses**

3
4 Luca M. Zaack^{1*}, Ngoc H. Tan^{2*}, Wim J.R. Rietdijk², Daryl Geers¹, Roos S.G. Sablerolles²,
5 Susanne Bogers¹, Laura L.A. van Dijk¹, Lennert Gommers¹, Leanne P.M. van Leeuwen¹,
6 Sharona Rugebregt¹, Abraham Goorhuis^{3,4}, Douwe F. Postma⁵, Leo G. Visser⁶, Virgil A.S.H.
7 Dalm⁷, Melvin Lafeber⁸, Neeltje A. Kootstra⁹, Anke L.W. Huckriede¹⁰, Bart L. Haagmans¹,
8 Debbie van Baarle^{10,11}, Marion P.G. Koopmans¹, P. Hugo M. van der Kuy^{2#}, Corine H.
9 GeurtsvanKessel^{1#}, Rory D. de Vries^{1#}, SWITCH-ON Research Group[%]

10
11 ¹ Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands

12 ² Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, the Netherlands

13 ³ Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University
14 Medical Centers, Amsterdam, the Netherlands

15 ⁴ Infection & Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, the Netherlands

16 ⁵ Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the
17 Netherlands

18 ⁶ Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

19 ⁷ Department of Internal Medicine, Division of Allergy & Clinical Immunology and Department of Immunology,
20 Erasmus Medical Center, Rotterdam, the Netherlands

21 ⁸ Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

22 ⁹ Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam Infection and
23 Immunity Institute, University of Amsterdam, Amsterdam, the Netherlands

24 ¹⁰ Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of
25 Groningen, Groningen, the Netherlands

26 ¹¹ Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the
27 Netherlands

28
29 * Contributed equally

30 # Contributed equally

31
32 [%] List of investigators from the SWITCH-ON research group is in **Supplementary Table S1**

33
34 [§] corresponding author: Corine H. GeurtsvanKessel, department of Viroscience, Erasmus
35 Medical Center, Rotterdam, 3015 GD, Netherlands, c.geurtsvankessel@erasmusmc.nl

37 **Summary**

38 Waning antibody responses after COVID-19 vaccination combined with the emergence of the
39 SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure,
40 bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination
41 with that of Omicron BA.1 or BA.5 were introduced. Since then, BA.2-descendent lineages have
42 become dominant, such as XBB.1.5 or BA.2.86. Here, we assessed how different COVID-19
43 priming regimens affect the immunogenicity of the recently used bivalent booster vaccinations
44 and breakthrough infections. BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies
45 and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor.
46 Interestingly, different combinations of prime-boost regimens induced divergent responses:
47 participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent
48 boost while neutralization and T-cell responses were similar to mRNA-based primed
49 participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent
50 BA.5 boosted participants. Combined, we highlight important 'lessons learned' from the
51 employed COVID-19 vaccination strategies. Our data further support the use of monovalent
52 vaccines based on circulating strains when vaccinating risk groups, as recently recommended
53 by the WHO. We emphasize the importance of the continuous assessment of immune
54 responses targeting circulating variants to guide future COVID-19 vaccination policies.

55

56 **Keywords**

57 COVID-19, vaccination, SARS-CoV-2, neutralizing antibodies, immunity, bivalent vaccine,
58 adenovirus, mRNA.

59

60 **Introduction**

61 Vaccination against coronavirus disease-2019 (COVID-19) provides protection against infection,
62 hospitalization, and mortality^{1,2}. However, ongoing waning of severe acute respiratory syndrome
63 coronavirus-2 (SARS-CoV-2)-specific immune responses and the continuous evolution of
64 antigenically distinct variants result in an overall reduction of vaccine effectiveness³. The
65 currently circulating Omicron BA.2-descendent variants such as XBB.1.5 are the most immune
66 evasive to date⁴⁻⁶. This leads to an ongoing arms race: adapted vaccines are required to retain
67 effective protection on a population level, especially in vulnerable at-risk patients, in the face of
68 new emerging variants. As a countermeasure, mRNA-based bivalent vaccines incorporating an
69 Omicron BA.1 or BA.5 spike (S) protein in combination with the ancestral S were introduced in
70 2022^{7,8}.

71

72 While mRNA-based vaccines, including BNT162b2 and mRNA-1273, were initially shown to
73 have higher vaccine efficacy over adenovirus-vectored vaccines (Ad26.COV2.S and ChAdOx1-
74 S) in a primary vaccination series^{3,9}, it is not known whether the different original priming
75 regimens have a long-lasting imprinting effect on the magnitude, durability, or breadth of the
76 SARS-CoV-2-specific immune response¹⁰. Heterologous COVID-19 vaccination with different
77 vaccine platforms but the same S antigen was demonstrated to be at least non-inferior
78 regarding immunogenicity when compared to homologous priming with either mRNA-based or
79 adenovirus-based vaccines alone¹¹⁻¹³. Shaping of the immune response as a consequence of
80 exposure to different S antigens was mostly studied in the context of hybrid immunity, a
81 combination of vaccination and infection. These studies showed evidence for serological
82 imprinting to the ancestral S protein, but also the induction of variant-specific immune
83 responses¹⁴⁻¹⁶.

84

85 The SWITCH-ON trial^{17,18} aimed to evaluate the mRNA-based bivalent BA.1 and BA.5 booster
86 vaccines developed by Pfizer (BNT162b2) or Moderna (mRNA-1273.214 and mRNA-1273.222)
87 against the background of different priming regimens (mRNA-based or adeno-based), by
88 addressing three crucial questions: (1) How immunogenic are Omicron BA.1 or BA.5 bivalent
89 booster vaccines? (2) Do BA.1 or BA.5 bivalent booster vaccines differ in the induction of broad
90 neutralizing antibody responses, including adequate neutralization of XBB-descendent variants?
91 (3) How do immune responses among different original priming vaccination regimens evolve
92 over time and what can we learn for the future?

93

94 **Results**

95

96 **Study design and baseline characteristics**

97 A total of 434 healthcare workers (HCW) were included in the SWITCH-ON trial after screening
98 of 592 potential participants (**Figure 1**, baseline characteristics in **Supplementary Tables S2**
99 and **S3**). HCW received either Ad26.COV2.S or an mRNA-based (mRNA-1273 or BNT162b2)
100 priming vaccination regimen, followed by at least one mRNA-based booster vaccination before
101 inclusion in this study. The SWITCH-ON trial comprised two groups to which the participants
102 were randomly assigned: (1) a direct boost group (DB) (n=219, accounting for dropouts) or (2) a
103 postponed boost (PPB) group (n=183, accounting for dropouts). Participants in the DB group
104 were vaccinated in October 2022 with an Omicron BA.1 bivalent vaccine (BNT162b2 Omicron
105 BA.1 or mRNA-1273.214); participants in the PPB group were vaccinated in December 2022
106 with an Omicron BA.5 bivalent vaccine (BNT162b2 Omicron BA.5 or mRNA-1273.222).
107 Samples were collected before bivalent vaccination, at 7 and 28 days post-vaccination, and at
108 approximately 3 months post-vaccination (**Supplementary Figure S1**). No formal statistical
109 tests were performed to test for differences within or between groups as we deviated from the
110 original protocol in terms of pre-specified outcomes and a lower than anticipated sample size¹⁸.

111

112 **Bivalent COVID-19 vaccines induce antibody and T-cell responses**

113 The immunogenicity of Omicron BA.1 bivalent vaccines up to 28 days post-vaccination in the
114 SWITCH-ON trial was reported previously¹⁷. Both S-specific IgG binding and neutralizing
115 antibodies targeting ancestral SARS-CoV-2 increased within the first 28 days, with most of the
116 increase occurring between day 0 and 7 (**Figure 2a,b**). S-specific T-cell responses increased
117 rapidly in the first 7 days post-vaccination and subsequently waned (**Figure 2c**). At 3 months
118 post-vaccination, all of the measured immune parameters had decreased in comparison to the
119 previous study visit. Whereas antibodies did not yet wane to baseline levels, T-cell responses
120 returned close to baseline. The magnitude and kinetics of antibody and T-cell responses
121 induced by Omicron BA.5 bivalent booster vaccination were comparable to Omicron BA.1
122 bivalent boost, again with most of the increase occurring within the first 7 days (**Figure 2d-f**).
123 Overall, a comparable boost of (neutralizing) antibody and T-cell responses against ancestral
124 SARS-CoV-2 was observed after either Omicron BA.1 or BA.5 bivalent boost, independent of
125 the timing of vaccine administration.

126

127 **mRNA-based priming leads to higher binding antibody levels after bivalent boost**

128 The two groups (DB, Omicron BA.1 bivalent boost; PPB, Omicron BA.5 bivalent boost) could
129 each be subdivided into four subgroups, based on different priming and bivalent booster
130 regimens: (1) Ad26.COVS prime and mRNA-1273.214 or mRNA-1273.222 boost, (2)
131 Ad26.COVS prime and BNT162b2 Omicron BA.1 or BA.5 boost, (3) mRNA (mRNA-1273 or
132 BNT162b2)-based prime and mRNA-1273.214 or mRNA-1273.222 boost, and (4) mRNA-based
133 prime and BNT162b2 BA.1 or BA.5 boost (**Supplementary Figure S1**). Notably, Omicron BA.1-
134 and BA.5-boosted participants who had previously received an mRNA-based priming
135 vaccination regimen consistently had higher levels of S-specific binding antibodies than those
136 who received an Ad26.COVS priming (**Figure 3a,b**, compare green and blue to red and

137 yellow). This effect of the original priming was not observed for ancestral SARS-CoV-2
138 neutralizing antibodies or T-cell responses (**Supplementary Figure S2**). Of specific interest,
139 bivalent booster vaccination with mRNA-1273.214 or mRNA-1273.222 resulted in a larger
140 increase of binding and neutralizing antibodies than boosting with their BNT162b2 counterparts
141 did, indicating that these vaccines are more immunogenic (**Figure 3** and **Supplementary**
142 **Figure S3**). Both findings underline that different prime-boost regimens lead to divergent
143 immune responses.

144

145 **mRNA-based prime followed by BA.5 bivalent boost leads to broad neutralization**

146 Neutralizing antibodies against relevant Omicron variants BA.1 and BA.5 (encoded by the
147 vaccines), and XBB.1.5 (circulating) were measured to assess the breadth of the neutralization
148 response (**Figure 4a,b**). Comparable to ancestral SARS-CoV-2 neutralization, Omicron BA.1
149 and BA.5 neutralization were boosted by both the BA.1 and BA.5 bivalent booster vaccines;
150 however, levels remained below those for ancestral SARS-CoV-2 neutralization at all
151 timepoints. At 3 months post-vaccination, waning of neutralizing antibodies was observed.
152 Remarkably, when correlating ancestral- and variant-specific neutralizing antibody titers
153 (**Supplementary Figure S4**), it was clear that waning of Omicron BA.1 and BA.5 neutralizing
154 antibodies occurred at a slower rate compared to ancestral SARS-CoV-2 neutralizing
155 antibodies. This was true for both individuals boosted with the bivalent Omicron BA.1 (**Figure**
156 **4c,e**) or BA.5 vaccine (**Figure 4d,f**). The circulating Omicron XBB.1.5 was poorly cross-
157 neutralized at 3 months after bivalent boost, irrespective of the different prime-boost regimens
158 (**Figure 4a,b**). In participants boosted with the bivalent Omicron BA.5 vaccine, a preferential
159 boost of Omicron BA.5 neutralization was observed. This was not the case for Omicron BA.1
160 neutralizing antibodies in participants boosted with the bivalent Omicron BA.1 vaccine (**Figure**
161 **4g**, compare orange with purple radar plot). When subdividing participants boosted with bivalent
162 Omicron BA.5 in their respective prime-boost regimens, preferential boosting of Omicron BA.5

163 neutralization was restricted to participants who were primed with an mRNA-based vaccine
164 (**Figure 4h**). Participants primed with Ad26.COV2.S retained a narrow neutralizing response,
165 despite receiving the bivalent Omicron BA.5 booster.

166

167 **Breakthrough infections lead to comparatively low levels of immune responses**

168 In the PPB group, which was included in September 2022 but scheduled to receive the bivalent
169 Omicron BA.5 vaccine in December 2022, 13 test-confirmed infections were detected before
170 administration of the booster dose (**Figure 5a**). These participants were subsequently excluded
171 from the vaccine trajectory and analyzed separately as part of a natural infection-related sub-
172 study. Breakthrough infection before bivalent vaccination boosted S-specific binding antibodies
173 and T-cell responses. However, binding antibody levels 7 days (GMT 3,655 BAU/mL [95% CI
174 2,167-6,166]) and 28 days (GMT 5,025 BAU/mL [95% CI 3,264-7,737]) post-infection (**Figure**
175 **5b**) were considerably lower than compared to the same time interval post-vaccination (7d:
176 GMT 10,503 BAU/mL [95% CI 9,218-11,969]; 28d: GMT 12,814 BAU/mL [95% CI 11,271-
177 14,569], shown in **Figure 2d**). T-cell responses and Omicron neutralizing antibodies were
178 comparable to post-vaccination responses, although T-cell responses returned to baseline
179 faster compared to post-vaccination (**Figure 5c,d**). In addition, 59 breakthrough infections after
180 administration of either bivalent Omicron BA.1 or BA.5 booster vaccination were detected
181 through various methods (test-confirmed or detection of nucleocapsid-specific antibodies). Of
182 these participants, samples collected prior to infection were included in the preceding
183 immunogenicity analyses. Notably, breakthrough infection after Omicron BA.1 or BA.5 bivalent
184 boost did not result in an additional increase of antibody or T-cell responses in comparison to
185 the already vaccine-induced levels (**Supplementary Figure S5**). Overall, breakthrough
186 infections before and after vaccination were comparatively poorly immunogenic compared to
187 vaccine-induced immune responses.

188

189 Discussion

190 Here, we report that Omicron BA.1 or BA.5 bivalent booster vaccination results in rapid recall of
191 humoral and cellular immune responses, which wane at 3 months post-vaccination. By
192 simultaneously assessing multiple immune parameters, we found divergent immune responses
193 after distinct COVID-19 vaccination regimens.

194
195 The immunogenicity and boosting of SARS-CoV-2-specific immune responses by Omicron BA.1
196 or BA.5 bivalent vaccination was in line with previous studies^{7,17,19}. As published vaccination
197 trials often do not take original priming vaccination regimens into account, no studies to our
198 knowledge have assessed bivalent vaccine immunogenicity in the context of different priming
199 regimens. Here, we find two important differences between bivalent-boosted participants primed
200 with either Ad26.COV2.S or an mRNA-based vaccine: (1) mRNA-based priming leads to higher
201 antibody levels upon boost, and (2) BA.5-bivalent boost only led to broad neutralization profiles
202 in mRNA-primed participants. This could be related to biological differences between the
203 vaccine platforms, as it was already shown that the vaccine effectiveness for adenovirus-
204 vectored vaccines was lower compared to mRNA-based vaccines^{3,9}

205
206 When zooming in on the booster vaccines, mRNA-1273.214 and mRNA-1273.222 proved more
207 immunogenic than their BNT162b2 Omicron BA.1 and BA.5 counterparts. This supports a
208 recent Moderna-funded retrospective cohort study, which reported a greater effectiveness of
209 mRNA-1273.222 compared with BNT162b2 Omicron BA.5 in preventing COVID-19-related
210 hospitalizations and outpatient visits²⁰. The differences in immunogenicity and efficacy between
211 the Pfizer and Moderna vaccines are likely explained by differences in dose and/or antigen
212 design. At 3 month post-bivalent booster vaccination, we uniformly observed waning of all
213 measured immune parameters, consistent with previous reports^{21,22}. Interestingly, Omicron BA.1
214 and BA.5 neutralizing antibodies waned slower compared to ancestral SARS-CoV-2 neutralizing

215 antibodies after bivalent boost. The number of antigen exposures could be underlying this
216 observation; repeated exposure is thought to boost antibodies of the IgG4 subclass, potentially
217 affecting functionality²³.

218

219 Neutralizing antibodies are assumed to be the immunological correlate of protection against
220 symptomatic SARS-CoV-2 infection⁹ and severe disease²⁴. Based on this assumption, 'variant-
221 modified' booster vaccinations were predicted to offer an elevated level of protection²⁵. While
222 the overall effectiveness of Omicron bivalent vaccination has been described^{20,26-28}, we show
223 that the cross-neutralization of the circulating BA.2-descendent Omicron variant XBB.1.5 was
224 poor after administration of either the Omicron BA.1 or the BA.5 bivalent booster vaccine, in line
225 with previous reports⁴⁻⁶. It was recently demonstrated via receptor-binding domain (RBD)
226 depletion experiments that the immune response following an Omicron BA.5 bivalent booster
227 vaccination is primarily ancestral-specific and only cross-reactive towards BA.5, and that the
228 concentrations of BA.5-specific antibodies are low²⁹. This is in line with a report that spike-
229 binding monoclonal antibodies derived memory B-cells isolated from individuals boosted with
230 variant-modified mRNA vaccines (Beta/Delta bivalent or Omicron BA.1 monovalent)
231 predominantly recognized the ancestral SARS-CoV-2 spike protein, with only a low frequency of
232 *de novo* B-cells targeting variant-specific epitopes³⁰. Similarly, induction of new antibody
233 responses from naïve B cells was shown to be suppressed after sequential homologous
234 boosting¹⁵. As demonstrated by the low XBB.1.5 neutralizing antibody levels at 3 month post-
235 bivalent booster independent of the prime-boost regimen, it is logical to assume that these
236 antibodies are even less cross-reactive with potential future lineages that are antigenically even
237 more distinct^{31,32}. Their reliance on the *de novo* induction of antigen-specific B cells to maintain
238 vaccine effectiveness may be even larger. Consequently, this argues in favor of employing
239 monovalent vaccines based on emerging lineages in subsequent vaccination campaigns, as
240 recently recommended by the WHO³³.

241
242 The immunogenicity of SARS-CoV-2 breakthrough infections in comparison to booster
243 vaccinations has not been extensively studied. Although we had a relatively small study size,
244 and the variation between participants who had a breakthrough infection was large, we did find
245 that breakthrough infections appear not as immunogenic as vaccination. In participants that had
246 been enrolled but not yet vaccinated, a comparatively low boost of antibodies and rapidly
247 waning boost of T-cell responses was detected upon breakthrough. Furthermore, in participants
248 that had been vaccinated between 28 days and 3 months prior, no additional boost in S-specific
249 responses was detected upon breakthrough, likely because antibody and T-cell responses were
250 already relatively high. However, we only measured S-specific responses; breakthroughs could
251 have potentially boosted immune responses to other antigens. Additionally, it is unknown how
252 breakthrough infections with a variant effect protection from future infections.

253
254 Combined, our data emphasize important 'lessons learned' from the COVID-19 pandemic and
255 associated vaccination strategies: (1) the original priming vaccination has an imprinting effect on
256 the immune system that can still be observed after at least two mRNA-based booster vaccines,
257 and (2) not all mRNA-based booster vaccines are equally immunogenic; in the SWITCH-ON trial
258 only bivalent Omicron BA.5 vaccination broadened the neutralizing antibody response, whereas
259 the bivalent BA.1 vaccine did not. Our data support the recent vaccination advice from the WHO
260 (as of May 2023)³³ to vaccinate risk groups with monovalent vaccines based on the circulating
261 XBB.1-descendent lineage, as the current (bivalent) vaccines only induce limited cross-
262 neutralization. Our data emphasize the importance to continuously evaluate immune responses
263 and cross-reactivity with circulating variants to guide future COVID-19 vaccination policy
264 making.

265

266 **Methods**

267

268 **Study design and participants**

269 The SWITCH-ON study is an ongoing multicenter, open-label, randomized controlled trial, which
270 was conducted in accordance with the Declaration of Helsinki. Participants were randomized to
271 either the direct boost group (DB) or the postponed boost group (PPB), who received a booster
272 vaccination with an Omicron BA.1 or BA.5 bivalent vaccine in October or December 2022,
273 respectively. This article reports the data for both study groups covering the period from the day
274 of booster vaccination until 3 months post-vaccination. All participants involved in the study
275 have given written informed consent prior to the first study visit.

276

277 HCW between the age of 18 to 65 years were invited to join the SWITCH-ON trial from four
278 academic hospitals in the Netherlands (Amsterdam University Medical Center, Erasmus Medical
279 Center, Leiden University Medical Center, and University Medical Center Groningen). Eligible
280 participants were primed with either one/two dose(s) of adenovirus-based (Ad26.COVS) or
281 two doses of mRNA-based vaccine (BNT162b2 or mRNA-1273), and have received at least one
282 mRNA-based booster. Prior SARS-CoV-2 infections were allowed; however, the last booster
283 vaccination or SARS-CoV-2 infection had to have occurred at least 12 weeks before the bivalent
284 booster was due, as per advised interval between boosts from the National Institute for Public
285 Health and the Environment (RIVM)³⁴. Infection history was collected through a self-reported
286 questionnaire. The full list of inclusion and exclusion criteria can be found in the study
287 protocol¹⁸.

288

289 **Randomization and masking**

290 All eligible participants were randomized using Castor software to the DB (Omicron BA.1
291 bivalent boost) or PPB (Omicron BA.5 bivalent boost) group in a 1:1 ratio by block

292 randomization with block sizes of 16 and 24. Due to the set-up of the study, it was not possible
293 to blind participants from randomization. Therefore, participants were informed about their group
294 allocation prior to the first study visit. Randomization was completed by research assistants who
295 were not involved in statistical analyses. Laboratory personnel were not masked from
296 randomization allocations.

297

298 **Procedures**

299 Participants in the DB group received an Omicron BA.1 bivalent booster in October 2022. If
300 participants were younger than 45 years old, BNT162b2 Omicron BA.1 was administered;
301 mRNA-1273.214 was administered to participants 45 years and older. This age division was
302 introduced as per advice from the RIVM³⁴. Following consultation with the RIVM, the age
303 division was removed for the PPB group, and participants were randomized to receive the
304 Omicron bivalent booster vaccination with either BNT162b2 Omicron BA.5 or mRNA-1273.222.
305 In both groups, blood was taken during the first study visit (study visit 1, day 0). Additional blood
306 samples were collected in subsequent study visits: study visit 2 (day 7 ± 1 days after boost),
307 study visit 3 (day 28 ± 2 days after boost) and study visit 4 (day 90 ± 14 days after boost).

308

309 A baseline characteristics questionnaire was obtained after randomization to collect information
310 about year of birth, biological sex, height, weight, ancestry, occupation, history of SARS-CoV-2
311 infection, and history of COVID-19 vaccination. A few days prior to each study visit, participants
312 received a questionnaire to detect SARS-CoV-2 infections between the last and upcoming study
313 visit. Via this infection questionnaire, we could identify participants who had an infection during
314 the course of the study.

315 (1) If the infection occurred between the informed consent session and the first vaccination
316 study visit, participants were invited to join a sub-study to analyze immunological
317 response after natural infection and they would be excluded from vaccination trajectory.

318 In this sub-study, blood samples would be collected at 7 and 28 days after participants
319 tested positive (by at-home antigen test) for COVID-19 (**Figure 5**).

320 (2) If the infection occurred between baseline and day 28 post-vaccination, no additional
321 blood samples were taken as the mixed effect of natural infection and vaccination would
322 be difficult to distinguish. These participants were excluded from all analyses.

323 (3) If the infection occurred between study visits day 28 and 3 months post-vaccination,
324 participants would be invited for additional blood sampling on day 7 and 28 after they
325 had tested positive, and remained in the study. Samples collected prior to infection were
326 included in the immunogenicity analysis (**Supplementary Figure 5**).

327

328 **Outcomes**

329 According to the study protocol, the primary outcome was the fold change (i.e., geometric mean
330 ratio [GMR]) in antibody response between baseline and 28 days after boost across both
331 groups. Secondary outcomes were fast response, S-specific T-cell response and levels of
332 neutralizing antibodies^{17,18}. Here, we report observational data on magnitude and quality of the
333 immunological response. Therefore, a descriptive approach was used to describe the
334 immunogenicity of bivalent booster vaccinations over the period of 3 months following
335 vaccination. We measured S-specific IgG binding antibodies, S-specific T-cell responses, and
336 neutralization of the ancestral, BA.1, BA.5, and XBB.1.5 variants. Similar parameters were
337 analyzed in the infection sub-study.

338

339 **Identification of recent SARS-CoV-2 infection**

340 Infections were either identified via self-reporting of participants following a positive test result in
341 an at-home antigen test, or the detection of SARS-CoV-2 nucleocapsid (N)-specific antibodies.
342 N-specific antibodies were measured at baseline and at 3 month post-boost using the Abbott
343 SARS-CoV-2 IgG assay following the manufacturer's instructions. N-specific antibody levels

344 were expressed in a signal-to-cutoff (S/CO) ratio and the manufacturer-recommended cut-off for
345 positivity of ≥ 1.4 S/CO was used. If a participants had detectable N-specific antibodies at 3
346 month post-boost, the other timepoints at 7 and 28 days post-boost were also tested to narrow
347 down the moment of infection. All samples from the timepoint N-specific antibodies were
348 detectable (or increased at least two-fold) and onwards were excluded from the immunogenicity
349 analyses of bivalent booster vaccinations.

350

351 **Detection of SARS-CoV-2 S1-specific IgG antibodies**

352 S1-specific antibodies were measured as previously described³⁵, by Liaison SARS-CoV-2
353 TrimericS IgG assay (DiaSorin). The lower limit of detection (LLoD) was 4.81 BAU/mL and the
354 cut-off for positivity was 33.8 BAU/mL, according to manufacturer's instructions.

355

356 **Detection of SARS-CoV-2 neutralizing antibodies**

357 Serum samples were tested for the presence of neutralizing antibodies against ancestral SARS-
358 CoV-2, and the Omicron BA.1, BA.5, and XBB.1.5 variants in a plaque reduction neutralization
359 test (PRNT) as previously described¹⁷. Viruses were cultured from clinical material and
360 sequences were confirmed by next-generation sequencing: D614G (ancestral; GISAID: hCov-
361 19/Netherlands/ZH-EMC-2498), Omicron BA.1 (GISAID: hCoV-19/Netherlands/LI-SQD-
362 01032/2022), Omicron BA.5 (EVAg: 010V-04723; hCovN19/Netherlands/ZHNEMCN5892), and
363 Omicron XBB.1.5 (GISAID: hCov-19/Netherlands/NH-EMC-5667). The human airway Calu-3
364 cell line (ATCC HTB-55) was used to grow virus stocks and to conduct PRNT. Calu-3 cells were
365 cultured in OptiMEM supplemented with GlutaMAX (Gibco), penicillin (100 units/mL, Capricorn
366 Scientific), streptomycin (0.1 mg/mL, Capricorn Scientific), and 10% fetal bovine serum (FBS;
367 Sigma). Briefly, heat-inactivated sera were diluted two-fold serially diluted in OptiMEM without
368 FBS. The dilutions ranges were based on the respective variant and the S-specific binding
369 antibody level: ancestral SARS-CoV-2 (<1,500 BAU/mL: 1:10 – 1:1,280; 1,500 – 6,000 BAU/mL:

370 1:80 – 1:10,240; >6,000 BAU/mL: 1:640 – 1: 81,920), Omicron BA.1/BA.5 variants (<6,000
371 BAU/mL: 1:10 – 1:1280; >6,000 BAU/mL: 1:80 – 1: 10,240), Omicron XBB.1.5 variant (<6,000
372 BAU/mL: 1:10 – 1:1280; >6,000 BAU/mL: 1:40 – 1: 5,120). Four hundred PFU of either SARS-
373 CoV-2 variant in an equal volume of OptiMEM medium were added to the diluted sera and
374 incubated at 37°C for 1 hour. The antibody-virus mix was then transferred to Calu-3 cells and
375 incubated at 37°C for 8 hours. Afterwards, the cells were fixed in 10% neutral-buffered formalin,
376 permeabilized in 70% ethanol, and the plaques stained with a polyclonal rabbit anti-SARS-CoV-
377 2 nucleocapsid antibody (Sino Biological) and a secondary peroxidase-labeled goat-anti rabbit
378 IgG antibody (Dako). The signals were developed with a precipitate-forming TMB substrate
379 (TrueBlue; SeraCare/KPL) and the number of plaques per well was quantified with an
380 ImmunoSpot Image Analyzer (CTL Europe GmbH). The 50% reduction titer (PRNT50) was
381 estimated by calculating the proportionate distance between two dilutions from which the
382 endpoint titer was calculated. An infection control (without serum) and positive serum control
383 (Nanogam® 100 mg/mL, Sanquin) were included on every assay plate. When no neutralization
384 was observed, the PRNT50 was assigned a value of 10.

385

386 **Detection of T-cell responses by interferon gamma release assay (IGRA)**

387 The SARS-CoV-2-specific T-cell response was quantified using an interferon gamma (IFN- γ)
388 release assay (IGRA) in whole blood using the commercially available QuantiFERON SARS-
389 CoV-2 assay kit (QIAGEN) as previously described¹¹. The assay kit is certified for *in vitro*
390 diagnostic (IVD) use. Heparinized whole blood was incubated with three different SARS-CoV-2
391 antigens for 20 – 24 h using a combination of peptides stimulating both CD4+ and CD8+ T-cells
392 (Ag1, Ag2, Ag3). Mitogen- and carrier (NIL)-coated control tubes were included as positive
393 control and negative control, respectively. After incubation, plasma was obtained by
394 centrifugation, and IFN- γ production in response to antigen stimulation was measured by ELISA
395 (QuantiFERON SARS-CoV-2 ELISA Kit [certified for IVD use]; QIAGEN). Results were

396 expressed in international units (IU) IFN- γ /mL after subtraction of the NIL control values as
397 interpolated from a standard calibration curve. LLoD was 0.01 IU/mL and the responder cut-off
398 was 0.15 IU/mL, according to the manufacturer's instructions. Only data obtained with Ag2
399 (overlapping peptides covering the ancestral S protein) is shown in this manuscript.

400

401 **Statistical analysis**

402 A power calculation in the SWITCH-ON trial was performed to identify the number of
403 participants required per study arm, namely: (i) Ad26.COVID2.S prime in the DB group, (ii) mRNA-
404 based prime in the DB group, (iii) Ad26.COVID2.S prime in the PPB group and (iv) mRNA-based
405 prime in the PPB group. For each arm, 91 participants were required to reach 80% power at a
406 two-sided 5% significance level to detect a difference of 0.2 log₁₀-transformed in the fold
407 change of antibody response between vaccination day and 28 days after boost. This difference
408 was based on the previous HCW study performed at Erasmus MC³⁵, in which the mean fold
409 changes for adenovirus-primed participants and mRNA-primed participants were reported as
410 1.344 (SD 0.451) and 1.151 (0.449), respectively.

411

412 A descriptive analysis was used to report baseline characteristics of participants. For continuous
413 variables, mean and standard deviation (SD) were reported if the data have normal distribution.
414 Otherwise, median and interquartile range (IQR) were used for data with non-normal
415 distribution. Count and percentages were used to report categorical variables. For missing
416 values, no imputation was performed and data availability was reported in **Supplementary**
417 **Table S4**. Immunological data were reported as geometric mean titers or geometric means and
418 95% confidence intervals. Spearman correlations were reported in **Supplementary Figure S4**.
419 No formal statistical tests were performed to test for differences within or between groups as we
420 deviated from the original protocol in terms of pre-specified outcomes and a lower than
421 anticipated sample size¹⁸.

422 **Acknowledgements**

423 No private funding was received for these studies. The bivalent BA.5 vaccine mRNA-1273.222
424 was provided by Moderna. Moderna reviewed the final version of the manuscript, but had no
425 role in study design, data collection, data analysis, data interpretation, or writing of the report. All
426 other vaccines were supplied by the Center for Infectious Disease Control, National Institute for
427 Public Health and the Environment, the Netherlands (RIVM). Cohort images were created with
428 BioRender. This study was funded by the Netherlands Organization for Health Research and
429 Development (ZonMw), grant agreement 10430072110001. The funder of the study had no role
430 in study design, data collection, data analysis, data interpretation, or writing of the report.

431 432 **Author contributions statement**

433 PHMvdK, CHGvK, and RDdV conceptualized the trial. LMZ, NHT, WJRR, DG, and RDdV
434 performed the formal analysis. NHT, WJRR, RSGS, AG, DFP, LGV, VASHD, ML, NAK, ALWH,
435 DvB, MPGK, PHMvdK, CHGvK, and RDdV acquired funding. All authors were involved in the
436 investigation. LMZ, NHT, PHMvdK, CHGvK, and RDdV performed project administration. AG,
437 DFP, LGV, PHMvdK, CHGvK, and RDdV supervised the trial. RDdV visualized the results. LMZ,
438 NHT, PHMvdK, CGvK, and RDdV wrote the original draft of the manuscript. All authors
439 reviewed and edited the final version of the manuscript.

440 441 **Competing interests**

442 We declare no competing interests.

443 444 **Data availability**

445 Data from the present study are not part of public databases but are available upon reasonable
446 request from the corresponding author. Materials and samples are available upon reasonable
447 request, will be released via a material transfer agreement and can otherwise be obtained via

448 the included experimental protocols. The SARS-CoV-2 virus stocks are available through the
449 European Virus Archive Global.


450

451 **Code availability**

452 No specific code was written or generated for analysis of the data. Software use has been
453 disclosed.


454

455 **Figures**



456
 457 **Figure 1. SWITCH-ON trial enrollment.** A total of 592 healthcare workers (HCW) were
 458 screened for eligibility, of whom 434 were included and randomized 1:1 to the direct boost (n =
 459 219) and the postponed boost (n = 215) group. Following dropouts, a total of 183 HCW received
 460 an Omicron BA.5 bivalent vaccine in the postponed group.

461



462

463

464

465

466

467

468

469

470

471

472


473

474

475

476

Figure 2. Antibody and T-cell responses after bivalent booster vaccination. a-f, Detection of (ancestral) spike (S)-specific binding IgG antibodies (**a,d**), ancestral SARS-CoV-2 neutralizing antibodies (**b,e**), and T-cell responses measured by interferon-gamma (IFN- γ) release assay (IGRA) (**c,f**) after Omicron BA.1 (**a-c**) or BA.5 (**d-f**) bivalent booster vaccination at baseline, and 7 days, 28 days, and 3 months post-boost. Colors indicate the specific prime-boost regimen (red = Ad26.COVS prime, mRNA-1273.214 or mRNA-1273.222 boost; yellow = Ad26.COVS prime, BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-based prime, mRNA-1273.214 or mRNA-1273.222 boost; blue = mRNA-based prime, BNT162b2 Omicron BA.1 or BA.5 boost). Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers above the plots represent the respective geometric mean (titer) per timepoint. The line graphs next to each panel depict a time course of the respective geometric mean values with 95% confidence intervals.



477

478 **Figure 3. Antibody and T-cell responses after different original priming and bivalent**

479 **booster vaccinations. a,b, Detection of S-specific binding IgG antibody levels in subgroups**

480 **based on the different combinations original priming regimen after Omicron BA.1 (a) or BA.5 (b)**

481 **bivalent booster vaccination at baseline, and 7 days, 28 days, and 3 months post-boost (red =**

482 **Ad26.COVID.S prime, mRNA-1273.214 or mRNA-1273.222 boost; yellow = Ad26.COVID.S prime,**

483 **BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-based prime, mRNA-1273.214 or**

484 **mRNA-1273.222 boost; blue = mRNA-based prime, BNT162b2 Omicron BA.1 or BA.5 boost).**

485 Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the


486 bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers

487 above the plots represent the respective geometric mean (titer) per timepoint. The line graphs

488 next to each panel depict a time course of the respective geometric mean values with 95%

489 confidence intervals.

490



491


492 **Figure 4. Breadth of the neutralizing antibody response after bivalent booster**

493 **vaccination. a,b, Detection of neutralizing antibodies targeting ancestral SARS-CoV-2 and**


494 Omicron BA.1, BA.5, and XBB.1.5 variants after Omicron BA.1 (**a**) or BA.5 (**b**) bivalent booster
495 vaccination at baseline, and 7 days, 28 days, and 3 months post-boost. Colors indicate the
496 specific prime-boost regimen (red = Ad26.COV2.S prime, mRNA-1273.214 or mRNA-1273.222
497 boost; yellow = Ad26.COV2.S prime, BNT162b2 Omicron BA.1 or BA.5 boost; green = mRNA-
498 based prime, mRNA-1273.214 or mRNA-1273.222 boost; blue = mRNA-based prime,
499 BNT162b2 Omicron BA.1 or BA.5 boost). **c-f**, Correlation between PRNT50 titers against
500 ancestral SARS-CoV-2 and the Omicron BA.1 (**c,d**) or BA.5 (**e,f**) variants over time after
501 Omicron BA.1 (**c,e**) or BA.5 (**d,f**) vaccination at baseline, and 7 days, 28 days, and 3 months
502 post-boost. Colored symbols indicate the specific timepoints (yellow = baseline [0 d]; teal = 7 d;
503 purple = 28 d; orange = 77 d [**c,e**]/98 d [**d,f**]). The arrows connect the correlated geometric
504 means (+ 95% CI) per timepoint and visualize the neutralization kinetics. **g,h**, Spiderweb plots
505 depicting the variant-specific PRNT50 titers relative to ancestral SARS-CoV-2 neutralization (set
506 to 100%), after vaccination with bivalent Omicron BA.1 (**g**) or BA.5 (**g,h**). Data in panels **a,b** are
507 shown in box-and-whisker plots, with the horizontal lines indicating the median, the bounds of
508 the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers above the
509 plots represent the respective geometric mean (titer) per timepoint. The line graphs next to each
510 panel depict a time course of the respective geometric mean values with 95% confidence
511 intervals.

512


a




b



c



d



513

514 **Figure 5. Breadth of the neutralizing antibody response after breakthrough infection. a,**

515 Sampling procedure for participants in the postponed boost group who had a breakthrough

516 infection before their intended vaccination with the bivalent Omicron BA.5 booster vaccine. They

517 were subsequently excluded from the vaccination trajectory and invited to participate in a sub-

518 study on the immunogenicity of natural SARS-CoV-2 infection. Samples were collected 7 and

519 28 days after the participants tested positive. **b-d**, Detection of (ancestral) S-specific binding IgG

520 antibodies (**b**), T-cell responses measured by IGRA (**c**), and neutralizing antibodies targeting

521 ancestral SARS-CoV-2 and Omicron BA.1, BA.5, and XBB.1.5 variants (**d**) before, and 7 and 28

522 days after breakthrough infection, which was contracted before intended vaccination with the

523 bivalent Omicron BA.5 booster vaccine (red = Ad26.COVID.S prime; blue mRNA-based prime).

524 Data are shown in box-and-whisker plots, with the horizontal lines indicating the median, the

525 bounds of the boxes indicating the IQR, and the whiskers indicating the range. Bold numbers

526 above the plots represent the respective geometric mean (titer) per timepoint. The line graphs

527 next to each panel depict a time course of the respective geometric mean values with 95%

528 confidence intervals.

529 References

- 530 1. Watson, O.J., Barnsley, G., Toor, J., Hogan, A.B., Winskill, P., and Ghani, A.C. (2022).
531 Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
532 *Lancet Infect Dis* 22, 1293-1302. [10.1016/S1473-3099\(22\)00320-6](https://doi.org/10.1016/S1473-3099(22)00320-6).
- 533 2. Suthar, A.B., Wang, J., Seffren, V., Wiegand, R.E., Griffing, S., and Zell, E. (2022).
534 Public health impact of covid-19 vaccines in the US: observational study. *BMJ* 377,
535 e069317. [10.1136/bmj-2021-069317](https://doi.org/10.1136/bmj-2021-069317).
- 536 3. Wu, N., Joyal-Desmarais, K., Ribeiro, P.A.B., Vieira, A.M., Stojanovic, J., Sanuade, C.,
537 Yip, D., and Bacon, S.L. (2023). Long-term effectiveness of COVID-19 vaccines against
538 infections, hospitalisations, and mortality in adults: findings from a rapid living systematic
539 evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir Med* 11,
540 439-452. [10.1016/S2213-2600\(23\)00015-2](https://doi.org/10.1016/S2213-2600(23)00015-2).
- 541 4. Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H.C., Ren, P., Xie, X., and Shi, P.Y.
542 (2023). Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by
543 parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med* 29, 344-347.
544 [10.1038/s41591-022-02162-x](https://doi.org/10.1038/s41591-022-02162-x).
- 545 5. Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A.D., Liu, M., Wang, M.,
546 Yu, J., et al. (2023). Alarming antibody evasion properties of rising SARS-CoV-2 BQ and
547 XBB subvariants. *Cell* 186, 279-286 e278. [10.1016/j.cell.2022.12.018](https://doi.org/10.1016/j.cell.2022.12.018).
- 548 6. Yue, C., Song, W., Wang, L., Jian, F., Chen, X., Gao, F., Shen, Z., Wang, Y., Wang, X.,
549 and Cao, Y. (2023). ACE2 binding and antibody evasion in enhanced transmissibility of
550 XBB.1.5. *Lancet Infect Dis* 23, 278-280. [10.1016/S1473-3099\(23\)00010-5](https://doi.org/10.1016/S1473-3099(23)00010-5).
- 551 7. Chalkias, S., Harper, C., Vrbicky, K., Walsh, S.R., Essink, B., Brosz, A., McGhee, N.,
552 Tomassini, J.E., Chen, X., Chang, Y., et al. (2022). A Bivalent Omicron-Containing
553 Booster Vaccine against Covid-19. *N Engl J Med* 387, 1279-1291.
554 [10.1056/NEJMoa2208343](https://doi.org/10.1056/NEJMoa2208343).

- 555 8. Winokur, P., Gayed, J., Fitz-Patrick, D., Thomas, S.J., Diya, O., Lockhart, S., Xu, X.,
556 Zhang, Y., Bangad, V., Schwartz, H.I., et al. (2023). Bivalent Omicron BA.1-Adapted
557 BNT162b2 Booster in Adults Older than 55 Years. *N Engl J Med* 388, 214-227.
558 10.1056/NEJMoa2213082.
- 559 9. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A.,
560 Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing
561 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-
562 2 infection. *Nat Med* 27, 1205-1211. 10.1038/s41591-021-01377-8.
- 563 10. Zaeck, L.M., GeurtsvanKessel, C.H., and de Vries, R.D. (2023). COVID-19 vaccine
564 effectiveness and evolving variants: understanding the immunological footprint. *Lancet*
565 *Respir Med* 11, 395-396. 10.1016/S2213-2600(23)00140-6.
- 566 11. Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Geers,
567 D., Schmitz, K.S., Garcia Garrido, H.M., Koopmans, M.P.G., Dalm, V., et al. (2022).
568 Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COVS.2.S Priming. *N*
569 *Engl J Med* 386, 951-963. 10.1056/NEJMoa2116747.
- 570 12. Atmar, R.L., Lyke, K.E., Deming, M.E., Jackson, L.A., Branche, A.R., El Sahly, H.M.,
571 Rostad, C.A., Martin, J.M., Johnston, C., Rupp, R.E., et al. (2022). Homologous and
572 Heterologous Covid-19 Booster Vaccinations. *N Engl J Med* 386, 1046-1057.
573 10.1056/NEJMoa2116414.
- 574 13. Hillus, D., Schwarz, T., Tober-Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch,
575 S., Helbig, E.T., Lippert, L.J., Tscheak, P., et al. (2021). Safety, reactogenicity, and
576 immunogenicity of homologous and heterologous prime-boost immunisation with
577 ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet Respir Med* 9,
578 1255-1265. 10.1016/S2213-2600(21)00357-X.
- 579 14. Reynolds, C.J., Gibbons, J.M., Pade, C., Lin, K.M., Sandoval, D.M., Pieper, F., Butler,
580 D.K., Liu, S., Otter, A.D., Joy, G., et al. (2022). Heterologous infection and vaccination

- 581 shapes immunity against SARS-CoV-2 variants. *Science* 375, 183-192.
582 10.1126/science.abm0811.
- 583 15. Schiepers, A., van 't Wout, M.F.L., Greaney, A.J., Zang, T., Muramatsu, H., Lin, P.J.C.,
584 Tam, Y.K., Mesin, L., Starr, T.N., Bieniasz, P.D., et al. (2023). Molecular fate-mapping of
585 serum antibody responses to repeat immunization. *Nature* 615, 482-489.
586 10.1038/s41586-023-05715-3.
- 587 16. Baerends, E.A.M., Reekie, J., Andreasen, S.R., Staerke, N.B., Raben, D., Nielsen, H.,
588 Petersen, K.T., Johansen, I.S., Lindvig, S.O., Madsen, L.W., et al. (2023). Omicron
589 variant-specific serological imprinting following BA.1 or BA.4/5 bivalent vaccination and
590 previous SARS-CoV-2 infection: A cohort study. *Clin Infect Dis*. 10.1093/cid/ciad402.
- 591 17. Tan, N.H., Geers, D., Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F.,
592 Visser, L.G., Bogers, S., van Dijk, L.L.A., Gommers, L., et al. (2023). Immunogenicity of
593 bivalent omicron (BA.1) booster vaccination after different priming regimens in health-
594 care workers in the Netherlands (SWITCH ON): results from the direct boost group of an
595 open-label, multicentre, randomised controlled trial. *Lancet Infect Dis* 23, 901-913.
596 10.1016/S1473-3099(23)00140-8.
- 597 18. Tan, N.H., Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser,
598 L.G., Bogers, S., Geers, D., Zaeck, L.M., Koopmans, M.P.G., et al. (2022). Analyzing the
599 immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON
600 trial protocol. *Front Immunol* 13, 1067749. 10.3389/fimmu.2022.1067749.
- 601 19. Collier, A.Y., Miller, J., Hachmann, N.P., McMahan, K., Liu, J., Bondzie, E.A., Gallup, L.,
602 Rowe, M., Schonberg, E., Thai, S., et al. (2023). Immunogenicity of BA.5 Bivalent mRNA
603 Vaccine Boosters. *N Engl J Med* 388, 565-567. 10.1056/NEJMc2213948.
- 604 20. Kopel, H., Nguyen, V.H., Boileau, C., Bogdanov, A., Winer, I., Ducruet, T., Zeng, N.,
605 Bonafede, M., Esposito, D.B., Martin, D., et al. (2023). Comparative Effectiveness of the
606 Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and

- 607 BNT162b2 Bivalent in Adults in the United States. medRxiv.
608 10.1101/2023.07.12.23292576.
- 609 21. Chalkias, S., Harper, C., Vrbicky, K., Walsh, S., Essink, B., Brosz, A., McGhee, N.,
610 Tomassini, J., Chen, X., Chang, Y., et al. (2022). Three-month Antibody Persistence of a
611 Bivalent Omicron-containing Booster Vaccine Against COVID-19. Research Square.
612 10.21203/rs.3.rs-2239682/v1.
- 613 22. Favresse, J., Gillot, C., Closset, M., Cabo, J., Wauthier, L., David, C., Elsen, M., Dogné,
614 J.-M., and Douxfils, J. (2023). Durability of humoral and cellular immunity six months
615 after the BNT162b2 bivalent booster. Authorea. 10.22541/au.168983668.85960360/v1.
- 616 23. Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil,
617 M., Beileke, S., Schafer, S., Zhong, J., et al. (2023). Class switch toward
618 noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA
619 vaccination. *Sci Immunol* 8, eade2798. 10.1126/sciimmunol.ade2798.
- 620 24. Cromer, D., Steain, M., Reynaldi, A., Schlub, T.E., Khan, S.R., Sasson, S.C., Kent, S.J.,
621 Khoury, D.S., and Davenport, M.P. (2023). Predicting vaccine effectiveness against
622 severe COVID-19 over time and against variants: a meta-analysis. *Nat Commun* 14,
623 1633. 10.1038/s41467-023-37176-7.
- 624 25. Khoury, D.S., Docken, S.S., Subbarao, K., Kent, S.J., Davenport, M.P., and Cromer, D.
625 (2023). Predicting the efficacy of variant-modified COVID-19 vaccine boosters. *Nat Med*
626 29, 574-578. 10.1038/s41591-023-02228-4.
- 627 26. Andersson, N.W., Thiesson, E.M., Baum, U., Pihlstrom, N., Starrfelt, J., Faksova, K.,
628 Poukka, E., Meijerink, H., Ljung, R., and Hviid, A. (2023). Comparative effectiveness of
629 bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥ 50 years in
630 Nordic countries: nationwide cohort study. *BMJ* 382, e075286. 10.1136/bmj-2022-
631 075286.

- 632 27. Link-Gelles, R., Weber, Z.A., Reese, S.E., Payne, A.B., Gaglani, M., Adams, K.,
633 Kharbanda, A.B., Natarajan, K., DeSilva, M.B., Dascomb, K., et al. (2023). Estimates of
634 Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization
635 and Critical Illness Among Adults with and Without Immunocompromising Conditions -
636 VISION Network, September 2022-April 2023. *MMWR Morb Mortal Wkly Rep* 72, 579-
637 588. [10.15585/mmwr.mm7221a3](https://doi.org/10.15585/mmwr.mm7221a3).
- 638 28. Lin, D.Y., Xu, Y., Gu, Y., Zeng, D., Sunny, S.K., and Moore, Z. (2023). Durability of
639 Bivalent Boosters against Omicron Subvariants. *N Engl J Med* 388, 1818-1820.
640 [10.1056/NEJMc2302462](https://doi.org/10.1056/NEJMc2302462).
- 641 29. Carreno, J.M., Singh, G., Simon, V., Krammer, F., and group, P.V.I.s. (2023). Bivalent
642 COVID-19 booster vaccines and the absence of BA.5-specific antibodies. *Lancet*
643 *Microbe*. [10.1016/S2666-5247\(23\)00118-0](https://doi.org/10.1016/S2666-5247(23)00118-0).
- 644 30. Alsoussi, W.B., Malladi, S.K., Zhou, J.Q., Liu, Z., Ying, B., Kim, W., Schmitz, A.J., Lei,
645 T., Horvath, S.C., Sturtz, A.J., et al. (2023). SARS-CoV-2 Omicron boosting induces de
646 novo B cell response in humans. *Nature* 617, 592-598. [10.1038/s41586-023-06025-4](https://doi.org/10.1038/s41586-023-06025-4).
- 647 31. Mykytyn, A.Z., Rosu, M.E., Kok, A., Rissmann, M., van Amerongen, G.,
648 Geurtsvankessel, C., de Vries, R.D., Munnink, B.B.O., Smith, D.J., Koopmans, M.P.G.,
649 et al. (2023). Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1,
650 BQ.1.1, and XBB.1. *Lancet Microbe* 4, e294-e295. [10.1016/S2666-5247\(22\)00384-6](https://doi.org/10.1016/S2666-5247(22)00384-6).
- 651 32. Mykytyn, A.Z., Rissmann, M., Kok, A., Rosu, M.E., Schipper, D., Breugem, T.I., van den
652 Doel, P.B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022). Antigenic cartography
653 of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. *Sci*
654 *Immunol* 7, eabq4450. [10.1126/sciimmunol.abq4450](https://doi.org/10.1126/sciimmunol.abq4450).
- 655 33. World Health Organization (2023). Statement on the antigen composition of COVID-19
656 vaccines. [https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-](https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines)
657 [composition-of-covid-19-vaccines](https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines).

- 658 34. RIVM (2023). Uitvoeringsrichtlijn - COVID-19-vaccinatie.
659 <https://lci.rivm.nl/richtlijnen/covid-19-vaccinatie>.
- 660 35. GeurtsvanKessel, C.H., Geers, D., Schmitz, K.S., Mykytyn, A.Z., Lamers, M.M., Bogers,
661 S., Scherbeijn, S., Gommers, L., Sablerolles, R.S.G., Nieuwkoop, N.N., et al. (2022).
662 Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine
663 recipients. *Sci Immunol* 7, eabo2202. 10.1126/sciimmunol.abo2202.
664